COVID-19 Vaccines

AUG 17, 2026 · JOURNAL ARTICLE

Pneumococcal vaccination status in critically ill patients: A cross-sectional study.

Human Vaccines & Immunotherapeutics

A single-centre cross-sectional survey with self-reported vaccination status and no clinical outcomes; findings describe a gap but cannot establish causation or guide clinical practice changes.

AUG 4, 2026 · JOURNAL ARTICLE

Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents.

Human Vaccines & Immunotherapeutics

A sound comparative immunogenicity study in a vulnerable population showing equivalent responses between two widely used vaccines, but limited by cross-sectional design, surrogate endpoints, and lack of clinical outcome data.

JUL 28, 2026 · JOURNAL ARTICLE

Analysis of vaccine adverse events associated with rheumatoid arthritis: A pharmacovigilance study based on the VAERS database.

Human Vaccines & Immunotherapeutics

Pharmacovigilance signal detection study using passive surveillance data identifying potential vaccine-RA associations, but explicitly unable to establish causality or confirm safety; findings are hypothesis-generating only.

JUL 26, 2026 · JOURNAL ARTICLE

Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023-24 in six European countries: a VEBIS-EHR network study.

Expert Review of Vaccines

Multi-country retrospective cohort study with confounder-adjusted hazard ratios and meta-analysis pooling, demonstrating moderate vaccine effectiveness against severe outcomes in a vulnerable population, though protection wanes over time.

JUL 7, 2026 · JOURNAL ARTICLE

Lymph node-targeted mRNA delivery of fine-tuned peptide-nanocomplexes for SARS-CoV-2 Vaccination.

Biomaterials

Preclinical mouse study demonstrates a novel peptide-nanocomplex delivery system with improved lymph node targeting and prolonged antigen expression compared to lipid nanoparticles, with comparable neutralizing antibody responses and superior CD8+ T cell responses, but lacks human data and clinical validation.

JUL 6, 2026 · REVIEW/PERSPECTIVE

Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.

Human Vaccines & Immunotherapeutics

A translational framework review synthesizing adjuvant mechanisms and design strategies without reporting original comparative data.

JUN 29, 2026 · JOURNAL ARTICLE

Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies.

Human Vaccines & Immunotherapeutics

Single-center retrospective audit of vaccination coverage in a regional CF cohort; documents suboptimal uptake for influenza and COVID-19 but lacks comparative design, causal analysis, or intervention testing to support practice change.

JUN 3, 2026 · JOURNAL ARTICLE

Characteristics of COVID-19 vaccine hesitancy in university students: Methodological insights from a syndemic perspective.

Human Vaccines & Immunotherapeutics

This is a methodological critique of another study, not a primary empirical investigation; it identifies significant limitations (recall bias, cross-sectional design, 11% response rate, dichotomization) that preclude strong causal or mechanistic claims about vaccine hesitancy syndemics in the original work.